RLN3 and depressive disorder: Although research in this area is still in its relative infancy (Smith et al., 2011), several key features have highlighted relaxin-3/RXFP3 systems as an attractive putative target for the treatment of cognitive deficits, and neuropsychiatric disorders, including depression.